

Multifunctional human CD56^{low} CD16^{low} natural killer cells are the prominent subset in bone marrow of both healthy pediatric donors and leukemic patients

Helena Stabile,¹ Paolo Nisti,¹ Stefania Morrone,² Daria Pagliara,³ Alice Bertaina,³ Franco Locatelli,³ Angela Santoni^{1,5} and Angela Gismondi^{1,4}

¹Department Molecular Medicine and ²Department Experimental Medicine, University of Rome "La Sapienza"; ³Department Pediatric Hematology/Oncology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ospedale Pediatrico Bambino Gesù, Rome and University of Pavia; ⁴Eleonora Lorillard Spencer Cenci Foundation, Rome; and ⁵Italian Institute of Technology, Genova, Italy


©2015 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2014.116053

Manuscript received on August 20, 2014. Manuscript accepted on January 14, 2015.

Correspondence: angela.gismondi@uniroma1.it

Supplemental Figure 1. Cytotoxic activity of PB and BM CD56^{high}CD16^{+/-} and CD56^{low} NK cell subsets.

BM and PB from healthy donors were co-cultured with K562 and degranulation ability of CD56^{high}CD16^{+/-} (black histogram) and CD56^{low} (white histogram) NK cell subsets, gated on CD56⁺CD3⁻, was assessed by evaluating the percentage of CD107a positive cells. The mean value \pm SD of 5 independent experiments is shown.



Supplemental Figure 1 (Stabile et al.)

Supplemental Table 1.

Patients	age at diagnosis (year)	sex	Diagnosis	Cytogenetics	SNC	% BM blast	% PB blast
#1	2	F	ALL common	TEL/AML1	no	45.2	ND
#2	3	M	ALL common	TEL/AML1	no	60	2
#3	2	F	ALL common	no	no	53	ND
#4	2	M	ALL Phi +	t (9;22)	no	74	55
#5	3	F	ALL common	no	no	29	1.2
#6	2	F	ALL common	no	no	85	ND
#7	7	F	ALL common	no	no	48	ND
#8	10	M	ALL common	no	no	40	ND
#9	4	M	ALL common	no	no	86	ND
#10	5	F	ALL common	no	no	79.4	5.5
#11	3	F	PRO-B ALL	no	no	92	ND
#12	4	F	ALL common	no	no	42	ND
#13	10	M	ALL common	no	no	76	ND
#14	3	M	ALL common	TEL/AML1	no	60	21
#15	2	M	ALL common	t (12;21)	no	64	4
#16	11	F	ALL T	no	no	95	93
#17	4	F	ALL T	no	no	85	72
#18	16	M	ALL T	no	no	ND	93
#19	13	F	ALL T	no	no	50	37

Supplemental Table 2.

List of antibodies used for flow cytometric phenotype of NK cells subsets

mAb	Clone	Provider
anti-CD3	SK7	BD Pharmingen
anti-CD16	3G8	BD Pharmingen
anti-CD25	2A3	BD Pharmingen
anti-CD27	M-T271	BD Pharmingen
anti-CD45	2D1	BD Pharmingen
anti-CD56	NCAM16.2	BD Pharmingen
anti-CD51	NK-1	BD Pharmingen
anti-CD62L	DREG-56	BD Pharmingen
anti-CD107a	H4A3	BD Pharmingen
anti-CD161	DX12	BD Pharmingen
anti-CXCR3	1C6	BD Pharmingen
anti-CXCR4	12G5	BD Pharmingen
anti-NKG2D	1D11	BD Pharmingen
anti-CD127	h-IL-7R-M21	BD Pharmingen
anti-CD158a	HP-5E4	BD Pharmingen
anti-CD158b	CH-L	BD Pharmingen
anti-CD158e1	DX9	BD Pharmingen
anti-CD226	DX-11	BD Pharmingen
anti-INF γ	B27	BD Pharmingen
IgG1	MOPC-21	BD Pharmingen
IgG2a	G155-178	BD Pharmingen
anti-CD159a	Z199.1	Beckman Coulter
anti-CD122	27302	R&D System
IgG1	CL133303	R&D System
rat anti-CX3CR1	2A9-1	Biolegend
rat IgG2a	RTK 4530	Biolegend